Another study showed that CRISPR/Cas9 could efficiently target PD-1 in tumor-infiltrating lymphocytes (TIL) to produce adoptive T-cell therapy (ACT) products based on TIL-deficient PD-1 molecules. Here, PDCD1 is linked to neoplasm.